Literature DB >> 21382130

Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit.

Rajesh Thomas1, John Ferguson, Geoffrey Coombs, Peter G Gibson.   

Abstract

BACKGROUND AND
OBJECTIVE: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains are primarily associated with skin and soft tissue infections; however, they are increasingly causing more invasive infections including severe community-acquired pneumonia. The objective of this study was to describe the clinico-pathological characteristics of community-acquired MRSA pneumonia.
METHODS: A retrospective analysis of case records from January 2002 to August 2008 was performed on patients admitted with community-acquired MRSA pneumonia to two large teaching hospitals.
RESULTS: Sixteen patients with community-acquired MRSA pneumonia were identified. Their age ranged from 11 months to 86 years (median age; 30 years). Duration of symptoms before hospital presentation ranged from one to 21 days. Most patients had productive cough, fever and dyspnoea. The most common radiological presentation included multilobar consolidation (8/16), necrotizing consolidation (7/16) and empyema (5/16). Seven patients required intensive care support; four required ionotropic support and five required mechanical ventilation for a mean duration of 53 h and 6.6 days, respectively. Six patients underwent surgery (VATS or open thoracotomy). There was a mean delay of approximately 69 h (range; 18 h to 11 days) after presentation before appropriate MRSA antimicrobial treatment was initiated. Three patients died of complications from pneumonia, all within 72 h of presentation. Among survivors, the average length of hospital stay was 23.8 days (range; 10-49 days). Majority of survivors were left with mild residual radiological changes.
CONCLUSIONS: Community-acquired MRSA pneumonia is increasing and should be suspected in patients with severe community-acquired pneumonia. There was a delay in initiation of appropriate antimicrobial treatment that could have lead to increased morbidity.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382130     DOI: 10.1111/j.1440-1843.2011.01965.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Pyng Lee
Journal:  Respirology       Date:  2012-04       Impact factor: 6.424

2.  Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia.

Authors:  A T Griffin; P Peyrani; T L Wiemken; J A Ramirez; F W Arnold
Journal:  Infection       Date:  2012-11-07       Impact factor: 3.553

3.  Molecular and clinical characteristics of clonal complex 59 methicillin-resistant Staphylococcus aureus infections in Mainland China.

Authors:  Juan Li; Lijuan Wang; Margaret Ip; Mingjiao Sun; Jing Sun; Guoying Huang; Chuanqing Wang; Li Deng; Yuejie Zheng; Zhou Fu; Changcong Li; Yunxiao Shang; Changan Zhao; Sangjie Yu; Kaihu Yao; Yonghong Yang; Xuzhuang Shen
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

4.  Community-Acquired Necrotizing Pneumonia Caused by ST72-SCCmec Type IV-Methicillin-Resistant Staphylococcus aureus in Korea.

Authors:  Ji-Won Hwang; Eun-Jeong Joo; Jung Min Ha; Woojoo Lee; Eun Kim; Sehyo Yune; Doo Ryeon Chung; Kyeongman Jeon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-08-30

5.  Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shao-Huan Lan; Shen-Peng Chang; Chih-Cheng Lai; Li-Chin Lu; Chien-Ming Chao
Journal:  J Clin Med       Date:  2019-06-09       Impact factor: 4.241

6.  Molecular characterization of methicillin-resistant Staphylococcus aureus isolated from tertiary care hospitals.

Authors:  Atif H Asghar
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.